Regenosca secures CHF 1M Pre-Seed funding to advance endoscopic delivery of innovative TissueSpan bio-implants

31.07.2024 09:25, Rita Longobardi

The pioneering biotech company Regenosca has secured CHF 1 million in Pre-Seed funding to advance its TissueSpan technology. These bio-implants help the body heal by attracting and organizing its cells, acting as a temporary bridge to replace diseased tissue. The funds will support the development of endoscopic delivery methods to improve the accessibility and effectiveness of TissueSpan implants.

Regenosca develops bio-implants that help the body heal by attracting and organizing its cells. The MedTech startup's TissueSpan technology acts as a temporary, naturally absorbed bridge to replace diseased tissue, restoring health.

Regenosca targets a market worth up to USD 5 billion annually, with an initial focus on urethral stricture, affecting up to a million US patients each year. Current treatments involve invasive surgery or less successful endoscopic procedures. Regenosca's human trials have shown perfect tissue regrowth.

The company raised CHF 1 million from private investors, Business Angels Switzerland, and Venture Kick. Its promising preclinical data and successful human trials have earned them awards at major urology conferences: the European Association of Urology, the Société Internationale d’Urologie, and the American Urological Association. Regenosca acknowledges support from Innosuisse, the Gebert Rüf Foundation, and Venture Kick, and welcomes new investors.

The MedTech startup participated in Venture Leaders Medtech in 2023 and won Venture Kick in 2020.


Regenosca team CTO Mattias Larsson CEO Eva-Maria Balet, and Clinical affaires responsible Ganesh Vythilingam